Skip to content

Medico-economic Evaluation of Subcutaneous Automatic Resorbable Staples Device

Medico-economic Evaluation of Subcutaneous Automatic Resorbable Staples Device

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01546272
Acronym
S2CARA
Enrollment
664
Registered
2012-03-07
Start date
2012-03-31
Completion date
2015-11-30
Last updated
2016-03-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ENT Surgery, Gynecological Surgery, Plastic Surgery

Keywords

Subcutaneous resorbable sutures, Tolerance / effectiveness of subcutaneous suture, Reduced operative time and anesthesia time, Medico-economic evaluation, Accidental exposure to blood

Brief summary

A surgery made by an external incision requires to stitch the subcutaneous plans, usually performed using absorbable synthetic sutures hold on wire needle. This national, prospective, multicentric, and randomized study is devoted to estimate a technique of suture of the subcutaneous plans based on an implantable medical device delivering automatically absorbable staples. This particularly innovative technique lets to expect a tolerance and an efficiency at least equivalent to the reference technique (main objective). Moreover, this technique allows to anticipate a reduction of the duration of surgical procedure and anesthetic time while limiting the risks of blood wounds of the medical staff.The medical economic part of this study will check, from the point of view of the health care hospital, wether the technique is likely to reduce the costs and time consuming theater room procedures.

Interventions

DEVICEInsorb resorbable staples

Subcutanous suture using resorbable staples

DEVICEMonocryl resorbable wire

Subcutanous suture using resorbable wire

Sponsors

Nantes University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Male or female aged 18 yrs to 75 yrs * Patient supported for a scheduled surgery : For abdominoplasty, cervicotomy or suprapubic surgery With a open incision necessary for operative exposition of 10 cm or more with a straight or curved surgery incision * Person covered by Health Insurance * ECOG Performance Status 0 or 1 * Patient's informed and written consent

Exclusion criteria

* Incision imposing a very angular or sinuous scar for which the use of the medical device is deemed unsuited (sinuous or bayonet incisions) * Known history of intolerance to any component of the medical device * Immunocompromised patients or undergoing a long term treatment by corticosteroids or immunosuppressants * Known or anticipated presence of a skin infection (due to the infected skin condition, or because of underlying surgery conducted in infected territory or likely to be) * Dermatological disease or skin treatment in progress * History of radiation therapy on the surgical site or antimitotic treatment in progress * Pregnancy at the time of suture * Patients simultaneously included in another treatment protocol * Patients under legal guardianship * Non French speaking patients, refusing or unfit for the monitoring proposed in the study

Design outcomes

Primary

MeasureTime frameDescription
Overall PSAS score measured 3 months after the surgery3 months after the surgeryOverall PSAS score measured 3 months after the surgery(PSAS : Patient Scar Assessment Scale)

Secondary

MeasureTime frameDescription
Presence of scarring complications at day 8 (infection, dehiscence)Day 8
Measurement of suture, surgical and anesthetic timesDay 0 (procedure)
Overall score of the PSAS scaleMonths 3, 12 and 18The tolerance will be assessed by the overall score of the PSAS scale (Patient Scar Assessment Scale)
Incremental cost-effectiveness ratio (ICER) or average cost of suture according to the procedure (wire or staple)Day 0 (Procedure)
Aesthetic quality of the scarMonth 18The aesthetic quality of the scar will be assessed by the patient and a physician (not the surgeon) by a score range from 0 to 10
Quantification of accidental exposure to bloodDuring the surgery
Overall score of the OSAS scaleMonths 3, 12 and 18The scar quality will be assessed by the overall score of the OSAS scale (Observer Scar Assessment Scale)

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026